AI models for cancer pathology often rely on shortcut correlations rather than detecting true biological signals, compromising reliability.
Key Details
- 1University of Warwick research analyzed 8,000+ patient samples across four cancer types using deep learning pathology models.
- 2Findings show many models predict biomarkers based on confounded visual cues, not causal biological features.
- 3AI models' headline accuracy can drop markedly when evaluated in stratified subgroups controlling for confounding factors.
- 4Reported accuracy for AI (just over 80%) was only modestly better than using tumour grade alone (~75%), already assessed by pathologists.
- 5Authors stress need for bias-aware evaluation and subgroup testing to prevent premature and unsafe clinical deployment.
Why It Matters
This research underscores significant risks of overrelying on AI diagnostic tools that may not generalize well in real-world settings. Robustness, causal modeling, and rigorous validation standards are essential before AI can safely supplement or replace human expertise in pathology and radiology.
Source
EurekAlert
Related News
•EurekAlert
AI Pathology Tool SÉMIL Improves Stage II Bowel Cancer Risk Assessment
A La Trobe University-developed AI tool accurately predicts relapse risk in stage II bowel cancer using digital pathology images and descriptions.
•EurekAlert
AI-Guided Handheld Cardiac Ultrasound Reduces Referrals and Costs in Spain
AI-guided handheld cardiac ultrasound enables primary care physicians to detect heart failure, reducing specialist referrals and saving costs.
•EurekAlert
AI Tool Predicts Which Rectal Cancer Patients Benefit from Intensive Therapy
UCL researchers developed an AI that analyzes biopsy slides to identify rectal cancer patients who benefit from adding irinotecan to standard chemoradiotherapy.